循环肿瘤DNA在可切除的非小细胞肺癌诊疗中的价值和研究进展  

The significance and advancements of circulating tumor DNA in the diagnosis and treatment of operable non-small cell lung cancer

作　　者：李紫凡 何越 陈克终[1] Li Zifan;He Yue;Chen Kezhong(Chinese Academy of Medical Sciences Research Innovation Unit of Intelligence Diagnosis and Treatment in Early Non-small-Cell Lung Cancer(2021RU002),Peking University People′s Hospital,Chinese Academy of Medical Sciences,Beijing 100044,China)

机构地区：[1]中国医学科学院,北京大学人民医院,中国医学科学院早期非小细胞肺癌智能诊疗创新单元(2021RU002),北京100044

出　　处：《中华外科杂志》2025年第2期171-176,共6页Chinese Journal of Surgery

基　　金：北京市自然科学基金-海淀原始创新联合基金(L222021);中国医学科学院医学与健康科技创新工程(2021-I2M-5-002);中国医学科学院临床与转化医学研究专项(2022-I2M-CT-B-120);雄安新区科技创新专项(2023XAGG0071);北京大学医学部学科建设项目临床医学+X青年专项(PKU2023LCXQ008);北京大学人民医院卓越青年项目(RZ2022-03)。

摘　　要：非小细胞肺癌具有发病率高和死亡率高的特点, 严重威胁着人类健康。如何精准评估患者预后并开展个体化治疗成为当前的热点问题, 基于液体活检的术后微小残留病灶(MRD)检测展现出了极大潜力。循环肿瘤DNA(ctDNA)可实时动态监测肿瘤变化, 随着相关检测技术的发展, ctDNA已成为评估MRD的核心手段。在术后监测上, ctDNA检测可实现更精确的患者预后分层, 并可早期预测肿瘤复发;在治疗上, ctDNA检测能够预测新辅助治疗及辅助治疗的效果。未来, 进一步揭示ctDNA用于评估患者预后及指导药物治疗的价值, 将有助于精准医疗和适应性治疗的开展。Non-small cell lung cancer,characterized by high incidence and mortality rates,significantly threatens human health.Precisely assessing patient prognosis and implementing adaptive treatment strategies have emerged as pivotal issues in contemporary thoracic oncology.Postoperative minimal residual disease(MRD)detection through liquid biopsy has demonstrated substantial potential.Circulating tumor DNA(ctDNA)enables real-time dynamic monitoring of tumor alterations.With advancements in ctDNA detection technologies,ctDNA has become a core method for MRD assessment.In the context of postoperative surveillance,ctDNA detection facilitates more accurate prognostic stratification and early prediction of tumor recurrence.Regarding therapeutic interventions,ctDNA detection can predict the efficacy of neoadjuvant and adjuvant therapies.In the future,further elucidating the value of assessing ctDNA status in predicting patient prognosis and guiding drug therapies will contribute to the advancement of precision medicine and adaptivetreatments.

关 键 词：癌 非小细胞肺 DNA 肿瘤 肿瘤 残余 

分 类 号：R734.2[医药卫生—肿瘤]